Happening now at #AACR26: Simon Bayle, PhD, shares how ULK1/2 inhibition may enhance KRAS-targeted therapies and help overcome resistance.

Key Findings:

• Structure-based drug design identified MR-2088 as a lead ULK1/2 inhibitor

• MR-2088 demonstrated synergy with sotorasib, enhancing tumor reduction in KRAS G12C NSCLC models

• Resistance appears driven by pathway dysregulation rather than clonal selection

• Alterations in metabolic and MYC signaling pathways align with drug-tolerant persister states

#MoffittAACR26 @AACR